Qiagen is partnering with Oxford Gene Technology, a Sysmex subsidiary, to comarket and distribute its Qiagen Clinical Insight (QCI) Interpret software with OGT's SureSeq NGS panels, the firms announced Thursday. Financial terms were not disclosed.

MGI Tech has reported that its revenues for the first half of 2025 dropped 8 percent year over year, mainly due to declining instrument sales.

One Biosciences, a French startup pursuing single-cell tumor RNA sequencing, said on Thursday that it has raised €15 million ($17.4 million) Series A financing.

MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, today announced a partnership with Negedia, an initiative born from Fondazione Telethon to expand access to DNBSEQ™-powered genomic sequencing and Stereo-seq spatial transcriptomics for precision medicine and biomedical research in Italy.

MGI Tech Co., Ltd. (“MGI”), a company dedicated to developing core tools and technologies that drive innovation in life sciences, and Asia Pathogen Genomics Initiative (“Asia PGI”) have recently announced collaboration aimed at enhancing pathogen genomics sequencing efforts across Asia. This collaboration underscores a shared commitment to supporting public health initiatives through advanced life science technology.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today a strategic collaboration with Broad Clinical Labs to develop and pilot groundbreaking applications using Roche’s recently unveiled next-generation sequencing (NGS) Sequencing By Expansion (SBX) technology. This collaboration will focus on harnessing the power of the SBX technology to transform clinical genomics and biomedical discovery. It will also aim to establish the SBX technology as a routine offering for fast, scalable sequencing for Broad Clinical Lab’s research community.

Targeted Genomics on Wednesday announced a commercial collaboration with OraSure Technologies for direct-to-consumer celiac disease testing using the OraCollect-Dx saliva collection device and GlutenID test.

GeneDx said Wednesday that it plans to acquire Fabric Genomics for $33 million in cash with the potential consideration rising to $51 million if certain milestones are met.

Oxford Nanopore Technologies, the company behind a new generation of sequencing-based molecular analysis technologies, and Cepheid, a leading molecular diagnostics company, today announced a strategic collaboration to develop and commercialize a seamless end-to-end workflow that combines Cepheid's GeneXpert system for pre-sequencing sample and library preparation with Oxford Nanopore's rapid, information-rich molecular analysis platform.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has partnered with Genomics England to support the delivery of the Generation Study.